Explain this page
Arphra AIPlain-English read on Aktis Oncology, Inc.’s valuation06-11today
- Aktis Oncology: Mini-Proteins With A Targeted Punch4d
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 202635d
- Aktis Oncology to Present at the BofA Securities Health Care Conference40d
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)42d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$0.62
-97.02% vs spot
Recommendation
Sell
3 of 4 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $35.33 (+70.76%)
Candlestick · 1Y
Open in chart workstation →AKTS
21.93-0.23%H 22.85L 14.72MA50 18.87MA200 —Avg vol 309K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.65% | +8.78% | +5.83% | +8.95% | -7.63% | -7.63% | -7.63% | -7.63% | -7.63% | -7.63% | -7.63% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$20.90
Bid
$20.00
100 sh
Ask
$25.00
1 sh
Spread
$5.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $1.87M | -$15.14M | $-0.28 |
| Q4 Dec 2024 | $933K | -$12.06M | $-0.23 |
Sector & industry today
LiveSectors
- Technology+2.09%
- Energy+1.31%
- Financial Services+1.26%
- Utilities+0.83%
- Basic Materials+0.81%
- Communication Services+0.46%
- Industrials+0.06%
- Consumer Cyclical-0.34%
- Healthcare-0.39%
- Real Estate-0.49%
- Consumer Defensive-0.59%
Top industries (issuer's industry highlighted)
- Biotechnology+2.27%
- Travel Services+7.28%
- Leisure+6.11%
- Solar+6.09%
- Manufacturing - Metal Fabrication+5.39%
- Electronic Gaming & Multimedia+5.39%
- Airlines, Airports & Air Services+5.14%
- Department Stores+5.04%
- Broadcasting-4.06%
- Packaging & Containers+3.76%
- Medical - Equipment & Services+3.70%
- Oil & Gas Exploration & Production-3.65%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Aktis Oncology: Mini-Proteins With A Targeted Punchseekingalpha.com·Jun 11, 2026
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026globenewswire.com·May 11, 2026
- Aktis Oncology to Present at the BofA Securities Health Care Conferenceglobenewswire.com·May 06, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
Recent analyst activity
DB- Jun 02, 2026GradeBuy → BuyAktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
- Jun 02, 2026PT$35.00Aktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
Peers
No peer list available for AKTS.
Total assets
$264.89M
Total debt
$11.55M
Cash & equiv
$37.78M
Operating CF
-$64.13M
Free cash flow
-$73.71M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $6.5M | -$74.68M | -$63.73M | $-1.19 | -980.93% |
| FY 2024 | $1.49M | -$52.05M | -$43.98M | $-1.26 | -2957.63% |
| FY 2023 | $0 | -$34.79M | -$28.64M | $-0.82 | — |
| FY 2022 | $0 | -$19.76M | -$17.93M | $-0.51 | — |